Folgen
Daniel Huebschmann
Daniel Huebschmann
Clinician scientist, group leader National Center for Tumor Diseases (NCT) Heidelberg and German
Bestätigte E-Mail-Adresse bei dkfz-heidelberg.de - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Pan-cancer analysis of whole genomes
Nature 578 (7793), 82-93, 2020
10532020
The landscape of genomic alterations across childhood cancers
SN Gröbner, BC Worst, J Weischenfeldt, I Buchhalter, K Kleinheinz, ...
Nature 555 (7696), 321-327, 2018
9452018
The whole-genome landscape of medulloblastoma subtypes
PA Northcott, I Buchhalter, AS Morrissy, V Hovestadt, J Weischenfeldt, ...
Nature 547 (7663), 311-317, 2017
7442017
Swarm learning for decentralized and confidential clinical machine learning
S Warnat-Herresthal, H Schultze, KL Shastry, S Manamohan, ...
Nature 594 (7862), 265-270, 2021
2312021
Integrative genomic and transcriptomic analysis of leiomyosarcoma
P Chudasama*, SS Mughal*, MA Sanders*, D Hübschmann*, I Chung, ...
Nature communications 9 (1), 1-15, 2018
1802018
Molecular evolution of early-onset prostate cancer identifies molecular risk markers and clinical trajectories
C Gerhauser, F Favero, T Risch, R Simon, L Feuerbach, Y Assenov, ...
Cancer Cell 34 (6), 996-1011. e8, 2018
1692018
Evolutionary trajectories of IDHWT glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis
V Körber, J Yang, P Barah, Y Wu, D Stichel, Z Gu, MNC Fletcher, D Jones, ...
Cancer cell 35 (4), 692-704. e12, 2019
1612019
Precision oncology based on omics data: the NCT Heidelberg experience
P Horak, B Klink, C Heining, S Gröschel, B Hutter, M Fröhlich, S Uhrig, ...
International journal of cancer 141 (5), 877-886, 2017
1282017
Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer
N Ishaque, ML Abba, C Hauser, N Patil, N Paramasivam, ...
Nature communications 9 (1), 4782, 2018
842018
Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma
C López*, K Kleinheinz*, SM Aukema*, M Rohde*, SH Bernhart*, ...
Nature communications 10 (1), 1-19, 2019
832019
Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19
B Krämer, R Knoll, L Bonaguro, M ToVinh, J Raabe, ...
Immunity 54 (11), 2650-2669. e14, 2021
812021
The landscape of chromothripsis across adult cancer types
N Voronina, JKL Wong, D Hübschmann, M Hlevnjak, S Uhrig, CE Heilig, ...
Nature communications 11 (1), 2320, 2020
662020
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification
S Gröschel, M Bommer, B Hutter, J Budczies, D Bonekamp, C Heining, ...
Molecular Case Studies 2 (6), a001180, 2016
642016
Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers
P Horak, C Heining, S Kreutzfeldt, B Hutter, A Mock, J Hüllein, M Fröhlich, ...
Cancer discovery 11 (11), 2780-2795, 2021
622021
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma
S Gröschel*, D Hübschmann*, F Raimondi, P Horak, G Warsow, ...
Nature communications 10 (1), 1-9, 2019
582019
Mutational patterns and regulatory networks in epigenetic subgroups of meningioma
N Paramasivam, D Hübschmann, UH Toprak, N Ishaque, M Neidert, ...
Acta neuropathologica 138, 295-308, 2019
552019
The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma
R Wagener, J Seufert, F Raimondi, S Bens, K Kleinheinz, I Nagel, ...
Blood, The Journal of the American Society of Hematology 133 (9), 962-966, 2019
522019
Analysis of Mutational Signatures with YAPSA (Yet Another Package for Signature Analysis)
D Hübschmann, L Jopp‐Saile, C Andresen, S Krämer, Z Gu, CE Heilig, ...
Genes, Chromosomes and Cancer, 2020
45*2020
Sex differences in oncogenic mutational processes
CH Li, SD Prokopec, RX Sun, F Yousif, N Schmitz, PC Boutros
Nature communications 11 (1), 4330, 2020
432020
Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity
R Hoefflin, B Lahrmann, G Warsow, D Hübschmann, C Spath, B Walter, ...
Nature Communications 7 (1), ncomms11845, 2016
412016
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20